USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/12083
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPasuta, Anna-
dc.date.accessioned2020-10-12T06:07:43Z-
dc.date.available2020-10-12T06:07:43Z-
dc.date.issued2020-
dc.identifier.citationPASUTA, Anna. Metformin for weight control in patients with schizophrenia. In: MedEspera: the 8th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2020, p. 359-360.en_US
dc.identifier.urihttps://medespera.asr.md/wp-content/uploads/ABSTRACT-BOOK.pdf-
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/12083-
dc.descriptionMassachusetts College of Pharmacy and Health Sciences, Boston, USA, The 8th International Medical Congress for Students and Young Doctors, September 24-26, 2020en_US
dc.description.abstractIntroduction. People use antipsychotic medications to manage schizophrenia as well as other disorders. The most bothersome side effect, especially for women is the weight gain associated with the use of antipsychotic medications. Currently there is no first line medication for weight control with antipsychotics. The mechanism of the weight gain by antipsychotics is unclear, however, it might be due to blocking of central histamine 1 (H1) or serotonin (5HT2c) receptors. It is suspected that naltrexone, an opioid antagonist, suppresses the desire for high fat foods via acting on D2 receptors. Metformin, however, is involved in appetite suppression and slowing of gastric emptying via promoting glucagon-like peptide-1 secretion. Thus, both these mechanisms might be able to counteract or prevent weight gain associated with antipsychotics use. Aim of the study. To determine whether metformin is more effective in weight loss after the use of antipsychotic medications. Materials and methods. PubMed database was used to search meshterms “antipsychotic, weight gain, metformin,” which were combined with “and” to result in 14 articles. After the addition of the filter “published within the last 5 years” was added, 5 articles were left. The meshterms “antipsychotic, weight gain, naltrexone” were combined with “and” to result in 3 articles. There were no articles with both drugs together. Embase database was searched from 1996 till 2017 week 02. Mapped key words “antipsychotic, weight gain, naltrexone” were filtered with randomized controlled trials within the last 5 years and combined with “and” which resulted in one article. Similarly key words “antipsychotic, weight gain, metformin” resulted in 5 articles. Two articles were not on the correct topic. Results. Metformin is shown to significantly reduce weight in schizophrenic patients by about 3 kg (2 RCTs; n=148, 45 women; and n=72, 32 women). Second study shows that metformin reduced initial body weight greater than was clinically significant (>7%, p=0.003). Naltrexone showed significant weight loss of 3.4 kg (CI=-5.16, -1.65, p=0.001) (1 RCT; n=24). No studies compared metformin and naltrexone in one trial. Metformin was shown to have more additional health benefits. Conclusions. Both metformin and naltrexone show statistically significant weight reduction in patients taking antipsychotics. However, metformin appears in more studies than naltrexone and shows additional health benefits like reduction of triglycerides. Thus, metformin appears to be more effective in weight control for women with schizophrenia. Pharmacists might be able to recommend metformin as an adjunct to the antipsychotic therapy.en_US
dc.language.isoenen_US
dc.publisherMedEsperaen_US
dc.subjectmetforminen_US
dc.subjectschizophreniaen_US
dc.subjectweight controlen_US
dc.titleMetformin for weight control in patients with schizophreniaen_US
dc.typeArticleen_US
Appears in Collections:MedEspera 2020

Files in This Item:
File Description SizeFormat 
Pasuta_Anna.pdf341.01 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback